BAYRY
The legal bill keeps coming
Bayer’s Monsanto unit is back in court, asking a Missouri judge to sign off on a $7.25 billion proposed settlement tied to Roundup lawsuits. The company says it’s basically out of runway here — no other deal, no other magic wand, just a giant check and a prayer that the litigation machine finally slows down.
Why investors should care
This isn’t just courtroom drama. Roundup has been one of those pesky, years-long overhangs that keeps reminding investors Bayer doesn’t only sell seeds, drugs, and crop science dreams — it also carries a very expensive legal backpack.
- A court-approved settlement could help cap a long-running risk
- But if the judge balks, the legal uncertainty sticks around like gum on your shoe
- And even with a deal, the cash hit is very real
Big picture
For Bayer shareholders, the question isn’t whether Roundup has been a headache. It’s whether this is finally the aspirin. If the settlement gets approved, the company may get a cleaner story to tell. If not, the litigation saga keeps writing new episodes.